Insulet Corp. Given Average Rating of “Hold” by Brokerages (NASDAQ:PODD)
Insulet Corp. (NASDAQ:PODD) has been given a consensus recommendation of “Hold” by the sixteen brokerages that are covering the company, American Banking & Market News reports. Two investment analysts have rated the stock with a sell recommendation, six have issued a hold recommendation and eight have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $37.10.
Several analysts have recently commented on the stock. Analysts at Canaccord Genuity raised their price target on shares of Insulet Corp. from $45.00 to $53.00 in a research note on Friday, January 24th. They now have a “buy” rating on the stock. Separately, analysts at Zacks downgraded shares of Insulet Corp. from a “neutral” rating to an “underperform” rating in a research note on Monday, January 13th. They now have a $34.40 price target on the stock. Finally, analysts at CRT Capital initiated coverage on shares of Insulet Corp. in a research note on Monday, January 6th. They set a “buy” rating and a $53.00 price target on the stock.
Shares of Insulet Corp. (NASDAQ:PODD) traded up 0.89% on Wednesday, hitting $44.14. The stock had a trading volume of 53,103 shares. Insulet Corp. has a 52-week low of $20.87 and a 52-week high of $44.61. The stock’s 50-day moving average is $39.93 and its 200-day moving average is $36.71. The company’s market cap is $2.407 billion.
In other Insulet Corp. news, Director Charles Liamos sold 11,037 shares of the company’s stock on the open market in a transaction dated Monday, February 3rd. The stock was sold at an average price of $42.93, for a total transaction of $473,818.41. Following the sale, the director now directly owns 77,316 shares of the company’s stock, valued at approximately $3,319,176. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
Insulet Corporation is primarily engaged in the development, manufacturing and sale of its OmniPod Insulin Management System (NASDAQ:PODD).
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.